Drug Trial Radar · NCT00981058
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,093
Actual
Start
Jan 7, 2010
Primary completion
Jun 17, 2013
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Parexel; PPD Development, LP; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific FS; ICON Clinical Research; Pacific Biomarkers; Sysmex Inostics GmbH; Intertek
- First posted
- Sep 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
Conditions
- Non Small Cell Lung Cancer
Interventions
NecitumumabBiological
Administered intravenously. Continues until progressive disease, toxicity, noncompliance, or withdrawal.
GemcitabineDrug
Administered intravenously. Continues for a maximum of six cycles.
CisplatinDrug
Administered intravenously. Continues for a maximum of six cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival Time (OS)Time frame: Randomization to Death from Any Cause (Up to 31 Months)
Locations
182 sites in 26 countries. Site status is shown where the registry gives one.
ImClone Investigational Site
Chandler, Arizona
ImClone Investigational Site
Fayetteville, Arkansas
ImClone Investigational Site
Sacramento, California
ImClone Investigational Site
Galesburg, Illinois
ImClone Investigational Site
Goshen, Indiana
ImClone Investigational Site
Wichita, Kansas
ImClone Investigational Site
Hazard, Kentucky
ImClone Investigational Site
Baltimore, Maryland
ImClone Investigational Site
Jefferson City, Missouri
ImClone Investigational Site
Lincoln, Nebraska
ImClone Investigational Site
New York, New York
ImClone Investigational Site
Akron, Ohio
ImClone Investigational Site
Camp Hill, Pennsylvania
ImClone Investigational Site
Memphis, Tennessee
ImClone Investigational Site
Fairfax, Virginia
ImClone Investigational Site
Garran, New South Wales, Australia
ImClone Investigational Site
Westmead, New South Wales, Australia
ImClone Investigational Site
Wollongong, New South Wales, Australia
ImClone Investigational Site
East Bentleigh, Victoria, Australia
ImClone Investigational Site
Geelong, Victoria, Australia
ImClone Investigational Site
Linz, Austria
ImClone Investigational Site
Vienna, Austria
ImClone Investigational Site
Vienna, Austria
ImClone Investigational Site
Duffel, Belgium
ImClone Investigational Site
Liège, Belgium
ImClone Investigational Site
Namur, Belgium
ImClone Investigational Site
Barretos, Brazil
ImClone Investigational Site
Brasilia, Distrito Federal, Brazil
ImClone Investigational Site
Goiânia, Brazil
ImClone Investigational Site
Ijuí, Brazil
ImClone Investigational Site
Itajaí, Brazil
ImClone Investigational Site
Lajeado, Brazil
ImClone Investigational Site
Porto Alegre/RS, Brazil
ImClone Investigational Site
Salvador, Brazil
ImClone Investigational Site
Santo André, Brazil
ImClone Investigational Site
São Paulo, Brazil
ImClone Investigational Site
São Paulo - SP, Brazil
ImClone Investigational Site
Saint John, New Brunswick, Canada
ImClone Investigational Site
Brampton, Ontario, Canada
ImClone Investigational Site
Saskatoon, Saskatchewan, Canada
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.